Santen Pharmaceutical Co., Ltd.

Tokyo Stock Exchange 4536.T

Santen Pharmaceutical Co., Ltd. Price to Sales Ratio (P/S) on February 07, 2025: 1.63

Santen Pharmaceutical Co., Ltd. Price to Sales Ratio (P/S) is 1.63 on February 07, 2025, a 1.05% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Santen Pharmaceutical Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 2.23 on August 23, 2024, which is 36.79% above the current Price to Sales Ratio (P/S).
Santen Pharmaceutical Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 1.60 on March 21, 2024, which is -1.76% below the current Price to Sales Ratio (P/S).
Santen Pharmaceutical Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 1.87.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Tokyo Stock Exchange: 4536.T

Santen Pharmaceutical Co., Ltd.

CEO	Mr. Takeshi Ito
IPO Date	Jan. 4, 2001
Location	Japan
Headquarters	Grand Front Osaka Tower A
Employees	3,744
Sector	Consumer Discretionary
Industries Eyewear Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Glass Pharmaceuticals Vaccines

Description

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Key trends

Past 5 years